Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New compounds could be used to treat autoimmune disorders

29.05.2019

The immune system is programmed to rid the body of biological bad guys--like viruses and dangerous bacteria--but its precision isn't guaranteed. In the tens of millions of Americans suffering from autoimmune diseases, the system mistakes normal cells for malicious invaders, prompting the body to engage in self-destructive behavior. This diverse class of conditions, which includes Type I diabetes, lupus, and multiple sclerosis, can be very difficult to treat.

In a new report in Nature Communications, researchers in the laboratory of Thomas Tuschl describe their development of small molecules that inhibit one of the main enzymes implicated in misguided immune responses. This research could lead to new treatments for people with certain autoimmune disorders and, more broadly, sheds light on the causes of autoimmunity.


Newly-developed molecules bind to a key enzyme pocket to inhibit its activity, and possibly prevent autoimmune responses.

Credit: Laboratory of RNA Molecular Biology at The Rockefeller University

Usage Restrictions: Image may be used to illustrate the research described in the accompanying release.

Cellular security

In eukaryotes, including humans, DNA typically resides in a cell's nucleus, or in other sequestered organelles such as mitochondria. So if DNA is found outside of these compartments--in the cell's cytosol--the immune system goes into high alert, assuming the genetic material was leaked by an invading bacterium or virus.

In 2013, researchers discovered an enzyme called cyclic GMP-AMP synthase, or cGAS, that detects and binds to cytosolic DNA to initiate a chain reaction--a cascade of cellular signaling events that leads to immune activation and usually ends with the destruction of the DNA-shedding pathogen.

Yet, cytosolic DNA isn't always a sign of infection. Sometimes it's produced by the body's own cells--and cGAS does not discriminate between infectious and innocuous DNA. The enzyme will bind to perfectly harmless genetic material, prompting an immune response even in the absence of an intruder.

"There is no specificity. So in addition to sensing foreign microbial DNA, cGAS will also sense aberrant cytosolic DNA made by the host," says postdoctoral associate Lodoe Lama. "And this lack of self versus non-self specificity could be driving autoimmune reactions."

Since the discovery of cGAS, researchers in the Tuschl laboratory have sought to understand its potential clinical relevance. If autoimmune disorders are the result of an erroneously activated immune system, then perhaps, they believe, a cGAS inhibitor could be used to treat these conditions.

Until now, no potent and specific small-molecule compound existed to block cGAS in human cells, though the researchers previously identified one that can do the job in mouse cells. Hoping to fill this gap, Tuschl's team collaborated with Rockefeller's High-Throughput and Spectroscopy Resource Center to scan through a library of almost 300,000 small molecules, searching for one that might target human cGAS.

Building a blocker

Through their screen, the researchers identified two molecules that showed some activity against cGAS--but this result was just the beginning of a long process towards developing an inhibitor that might be used in a clinical setting.

"The hits from library compounds were a great starting point, but they were not potent enough," says Lama. "So we used them as molecular scaffolds on which to make improvements, altering their structures in ways that would increase potency and also reduce toxicity."

Working with the Tri-Institutional Therapeutics Discovery Institute, the researchers modified one of their original scaffolds to create three compounds that blocked cGAS activity in human cells--making them the first molecules with this capability. Further analysis by researchers at Memorial Sloan Kettering Cancer Center revealed that the compounds inhibit cGAS by wedging into a pocket of the enzyme that is key to its activation.

The compounds are now being further optimized for potential use in patients, with an initial focus on treatment of the rare genetic disease Aicardi-Goutières syndrome. People with this condition accumulate abnormal cytosolic DNA that activates cGAS, leading to serious neurological problems. A drug that blocks the enzyme would therefore be of tremendous therapeutic value to those with the disease, who currently have few treatment options.

"This class of drug could potentially also be used to treat more common diseases, such as systemic lupus erythematosus, and possibly neurodegenerative diseases that include inflammatory contributions, such as Parkinson's disease," says Tuschl.

Further, the researchers believe that these compounds could serve as practical laboratory tools.

"Scientists will now have simple means by which to inhibit cGAS in human cells," says Lama. "And that could be immensely useful for studying and understanding the mechanisms that lead to autoimmune responses."

Media Contact

Katherine Fenz
kfenz@rockefeller.edu
212-327-7913

 @rockefelleruniv

http://www.rockefeller.edu 

Katherine Fenz | EurekAlert!
Further information:
https://www.rockefeller.edu/news/25972-new-compounds-used-treat-autoimmune-disorders/
http://dx.doi.org/10.1038/s41467-019-08620-4

More articles from Life Sciences:

nachricht New self-assembled monolayer is resistant to air
22.01.2020 | University of Groningen

nachricht Mosquitoes are drawn to flowers as much as people -- and now scientists know why
22.01.2020 | University of Washington

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New roles found for Huntington's disease protein

Crucial role in synapse formation could be new avenue toward treatment

A Duke University research team has identified a new function of a gene called huntingtin, a mutation of which underlies the progressive neurodegenerative...

Im Focus: A new look at 'strange metals'

For years, a new synthesis method has been developed at TU Wien (Vienna) to unlock the secrets of "strange metals". Now a breakthrough has been achieved. The results have been published in "Science".

Superconductors allow electrical current to flow without any resistance - but only below a certain critical temperature. Many materials have to be cooled down...

Im Focus: Programmable nests for cells

KIT researchers develop novel composites of DNA, silica particles, and carbon nanotubes -- Properties can be tailored to various applications

Using DNA, smallest silica particles, and carbon nanotubes, researchers of Karlsruhe Institute of Technology (KIT) developed novel programmable materials....

Im Focus: Miniature double glazing: Material developed which is heat-insulating and heat-conducting at the same time

Styrofoam or copper - both materials have very different properties with regard to their ability to conduct heat. Scientists at the Max Planck Institute for Polymer Research (MPI-P) in Mainz and the University of Bayreuth have now jointly developed and characterized a novel, extremely thin and transparent material that has different thermal conduction properties depending on the direction. While it can conduct heat extremely well in one direction, it shows good thermal insulation in the other direction.

Thermal insulation and thermal conduction play a crucial role in our everyday lives - from computer processors, where it is important to dissipate heat as...

Im Focus: Fraunhofer IAF establishes an application laboratory for quantum sensors

In order to advance the transfer of research developments from the field of quantum sensor technology into industrial applications, an application laboratory is being established at Fraunhofer IAF. This will enable interested companies and especially regional SMEs and start-ups to evaluate the innovation potential of quantum sensors for their specific requirements. Both the state of Baden-Württemberg and the Fraunhofer-Gesellschaft are supporting the four-year project with one million euros each.

The application laboratory is being set up as part of the Fraunhofer lighthouse project »QMag«, short for quantum magnetometry. In this project, researchers...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

11th Advanced Battery Power Conference, March 24-25, 2020 in Münster/Germany

16.01.2020 | Event News

Laser Colloquium Hydrogen LKH2: fast and reliable fuel cell manufacturing

15.01.2020 | Event News

„Advanced Battery Power“- Conference, Contributions are welcome!

07.01.2020 | Event News

 
Latest News

New self-assembled monolayer is resistant to air

22.01.2020 | Life Sciences

Ultrafast camera takes 1 trillion frames per second of transparent objects and phenomena

22.01.2020 | Power and Electrical Engineering

Mosquitoes are drawn to flowers as much as people -- and now scientists know why

22.01.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>